Paper Tools Add to my Library Share How would you like to share? Facebook Twitter LinkedIn Back to the Top
Mattke S. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease-Estimating the True Value. JAMA Neurol. 2022 Oct 3; PubMed. Recommends Please login to recommend the paper. Comments No Available Comments Make a Comment To make a comment you must login or register.
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.